Agency: Cordis | Branch: H2020 | Program: RIA | Phase: NFRP-09-2015 | Award Amount: 11.99M | Year: 2015
The Strategic Research Agenda of the EU Sustainable Nuclear Energy Technical platform requires new large infrastructures for its successful deployment. MYRRHA has been identified as a long term supporting research facility for all ESNII systems and as such put in the high-priority list of ESFRI. The goal of MYRTE is to perform the necessary research in order to demonstrate the feasibility of transmutation of high-level waste at industrial scale through the development of the MYRRHA research facility. Within MYRRHA as a large research facility, the demonstration of the technological performance of transmutation will be combined with the use for the production of radio-isotopes and as a material testing for nuclear fission and fusion applications. Numerical studies and experimental facilities are foreseen to reach this goal. Besides coordination, international collaboration and dissemination activities, the MYRTE proposal contains 5 technical work packages. The first and largest work-package is devoted to the realisation of the injector part of the MYRRHA accelerator to demonstrate the feasibility and required reliability of this non-semi-conducting part of the accelerator. The second work-package addresses the main outstanding technical issues in thermal hydraulics by numerical simulations and experimental validation. Pool thermal hydraulics and thermal hydraulics of the fuel assembly will be the focus of this WP. In the WP on LBE Chemistry, the evaporation from LBE, capture and deposition of Po and fission products will be studied in detail to complement the safety report. A small dedicated WP on experimental reactor physics is also foreseen to allow carrying out the necessary supplementary experiments at the GUINEVERE-facility to address the questions of the safety authorities. In a last WP, advanced studies on Americium-bearing oxide fuel are carried out to demonstrate the capability of developing minor actinide fuel for transmutation.
Ion Beam Applications S.A | Date: 2001-07-13
Apparatus and accelerator for electron-beam ionization, inspection and measurement, and parts therefor. Devices for electron beam irradiation for medical purposes, namely, x-ray apparatus, accelerators, biological shields, conveyors, and safety systems.
Agency: Cordis | Branch: FP7 | Program: MC-ITN | Phase: FP7-PEOPLE-2010-ITN | Award Amount: 3.82M | Year: 2011
The vision on a future high-precision radiation therapy utilizing either particle or photon beams is a treatment on a technological level which allows for: (1) obtaining information on relevant tumour parameters (volume, position, topology, density - also of the surrounding tissue) during every moment of therapeutic irradiation; (2) adapting the treatment plan in real time; and (3) initiating the appropriate control of the irradiation device to compensate for any deviations from the original treatment plan that compromise a tumour conformal dose delivery. The European training network in digital medical imaging for radiotherapy (ENTERVISION) will be established in response to the critical need for reinforcing research in online 3D digital imaging and the training of professionals in order to deliver some of the key elements and building blocks for realizing the vision for early detection and more precise treatment of tumours. This is an interdisciplinary (physics, medicine, electronics, informatics, radiobiology, engineering) multinational initiative, which has the primary goal of training researchers who will help technical developments at a pan-European level, for the benefit of all of Europe. ENTERVISION brings together ten academic institutes and research centres of excellence and the two leading European companies in particle therapy, IBA and Siemens. All partners are known worldwide in the diverse but complementary fields associated with technological development for improving health. Thus the network covers a unique set of competencies, expertise, infrastructures and training possibilities. The network will train 12 ESR and 4 ER during a 48 month period. The context of a new technique and a dynamic research program in an area of great societal demand offers outstanding training opportunities for future careers of the young researchers.
Agency: Cordis | Branch: H2020 | Program: MSCA-ITN-ETN | Phase: MSCA-ITN-2015-ETN | Award Amount: 3.87M | Year: 2016
Cancer is a major social problem, and it is the main cause of death between the ages 45-65 years. In the treatment of cancer, radio therapy (RT) plays an essential role. RT with hadrons (protons and light ions), due to their unique physical and radiobiological properties, offers several advantages over photons for specific cancer types. In particular, they penetrate the patient with minimal diffusion, they deposit maximum energy at the end of their range, and they can be shaped as narrow focused and scanned pencil beams of variable penetration depth. Although significant progress has been made in the use of particle beams for cancer treatment, an extensive research and development program is still needed to maximize the healthcare benefits from these therapies. The Optimization of Medical Accelerators (OMA) is the aim of the here-proposed European Training Network, in line with the requirements of the ECs Medical Exposure Directive. OMA joins universities, research centers and clinical facilities with industry partners to address the challenges in treatment facility design and optimization, numerical simulations for the development of advanced treatment schemes, and in beam imaging and treatment monitoring. The proposed R&D program ranges from life sciences (oncology, cell and micro biology and medical imaging.), physics and accelerator sciences, mathematics and IT, to engineering. It is hence ideally suited for an innovative training of early stage researchers. By closely linking all above research areas, OMA will provide an interdisciplinary education to its Fellows. This will equip them with solid knowledge also in research areas adjacent to their core research field, as well as with business competences and hence give them a perfect basis for a career in research.
Agency: Cordis | Branch: FP7 | Program: CP-CSA-Infra | Phase: INFRA-2008-1.1.2 | Award Amount: 11.23M | Year: 2009
ULICE is a 4-year project set up by 20 leading European research organisations, including 2 leading European industrial partners (Siemens and IBA), to respond to the need for greater access to hadron therapy facilities for particle therapy research. Project coordinator is the Italian Research Infrastructure Facility CNAO (Milan). Both existing European Hadron Research Facilities in Heidelberg and Milan are partner and together with the next operational centre (Philipps-Universitt Marburg; yr4) they will provide 624 hours of beam-time (141 users, 52 projects) to external researchers. Future facilities like MedAustron, Etoile and Archade also participate in ULICE, which will result in a strong integrated network. Full exploitation of all different resources, unrestricted spread of information and the improvement of existing and upcoming facilities are provided by using grid-based data sharing. The project is built around 3 pillars with measurable outputs. These outputs will be exploited by the (future) facilities and (partly by) the industrial partners: 1. JRA - focus on development of instruments and protocols: new gantry design, improvement of four-dimensional particle beam delivery, adaptive treatment planning, mechanisms for patient selection to the whole European Community and database development for specific tumours which can best be treated using carbon ion. 2. Networking - increasing cooperation between facilities and research communities wanting to work with the research infrastructure. Outputs will be (among others): a report on recommendations for strategically optimal locations for future RIs throughout Europe, training to new users 3. Transnational access: 2-step approach, using a combination of pre-defined (within ULICE) clinical trial programmes to allow researchers with patients to visit the facility, and radiobiological and physics experiments to take place.